
Best's Special Report: Secondary Perils Continue to Spike Insurer Loss Ratios, Even in Less Catastrophe-Prone States
The rising frequency of secondary perils in states considered to be less-catastrophe prone have led insurers to ramp up reassessments of their pricing models, underwriting strategies and risk management approaches.
Share
Secondary perils have become a major cause of loss in the past five years for U.S. property/casualty insurers with property catastrophe-exposed lines of business, highlighted by the January wildfires in California. In its Best's Special Report, 'US Weather Event Risks Highlight Need for Stress Testing,' AM Best states that insurers will need to stress test for these threats regularly as risk profiles evolve. Stress tests are conducted and factored in AM Best's credit rating process, as part of the balance sheet and enterprise risk management assessments.
'Stress testing should consider risk appetite and tolerance, as well as net exposure, the impact from multiple events, liquidity and reinsurance structure and dependence,' said Jason Hopper, associate director, Industry Research and Analytics. 'Understanding true exposures and considering all plausible scenarios is important. With the availability of aggregate reinsurance protection limited, some carriers have been severely impacted by the aggregation effects of multiple, smaller events.'
The report notes that there were 27 one-billion-dollar weather events in 2024, and 28 in 2023 (despite there being no NOAA-named hurricane), compared with an average of 15 events in 2010-2022. While national insurers have accounted for an overwhelming majority of direct losses paid, single-state and regional companies tend to have a greater share of claims compared with their premiums in some states, with Kentucky being the highest in 2023 at nearly 25% of direct losses paid in the state while having 18% in market share based on direct premiums. The greater share of claims than premiums indicates higher concentration risk for these carriers.
'Market disruptions continue as some of the national carriers curb their risk appetites, creating opportunities for single-state and regional writers,' said Jacob Conner, associate analyst, AM Best. 'However, the operating loss-drag on capital and surplus over the last 10 years has been worse for single-state and regional writers in catastrophe-prone states, and so stress testing helps companies determine the strength of the balance sheet and ability to absorb shocks.'
To access the full copy of this special report, please visit http://www3.ambest.com/bestweek/purchase.asp?record_code=353292.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
8 minutes ago
- Business Wire
GenSight Biologics Announces the Closing of the Company's c. €4 Million Private Placement
PARIS--(BUSINESS WIRE)--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the " Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the closing of its EUR 3,908,715.39 private placement (the ' Private Placement '). The Private Placement resulted in the issuance of 21,251,267 ordinary shares of the Company (the " Offered Shares"). The Offered Shares will be admitted to trading on Euronext Paris on July 3, 2025 (ISIN FR0013183985/SIGHT). The issuance of: The 1,850,000 pre-funded warrants (the " Offered Pre-Funded Warrants") giving the right to subscribe to 1,850,000 additional ordinary shares (the " Pre-Funded Warrant Shares"); and The 23,101,267 warrants (the " Offered Investor Warrants") giving the right to subscribe to 23,101,267 additional ordinary shares (the " Investor Warrant Shares") is expected to take place tomorrow, July 4, 2025. The Offered Investor Warrants will be admitted to trading on the Euronext Growth market in Paris (" Euronext Growth Paris") on July 7, 2025 (ISIN FR0014010IB4/SIGBS). The Offered Pre-Funded Warrants will not be admitted to trading on any venue. Part of the proceeds, EUR 0.7 million, has been used for the repayment in principal on the convertible bonds held by Heights Capital through offset against their subscription. Maxim Group, LLC acted as sole placement agent for the Private Placement in the United States, pursuant to an agreement entered into with the Company. Risk factors The Company draws the attention of the public to the risk factors relating to the Company and its business described in its 2024 Universal Registration Document, as amended by the Information Document published by the Company on July 1 st, 2025, both of which are available free of charge on the Company's website ( . About GenSight Biologics S.A. GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Disclaimer Not for release, directly or indirectly, in or into the United States of America, Canada, Australia, Japan or South Africa. This press release and the information contained herein do not contain or constitute an offer to subscribe or purchase, or the solicitation of an order to purchase or subscribe, for securities in the United States of America or in any other jurisdiction where such an offer or solicitation would be unlawful. The securities referred to herein have not been and will not be registered under the Securities Act, or under the securities laws of any state or other jurisdiction of the United States of America, and may not be offered or sold in the United States of America except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any state or any other jurisdiction of the United States. GenSight does not intend to make a public offering of the securities in the United States of America. The distribution of this press release may be subject to legal or regulatory restrictions in certain countries. Persons in possession of this press release should inform themselves of and observe any local restrictions. The information contained herein is subject to change without notice. Forward-Looking Statements This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the completion expected proceeds and anticipated use of proceeds of the Private Placement; the anticipated cash runway of the Company; and future expectations, plans and prospects of the Company. Words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'projects,' and 'future' or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the proposed Private Placement and the terms thereof are subject to numerous factors, many of which are beyond the control of the Company, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in the filings the Company makes with the AMF from time to time. The Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.


Business Wire
17 minutes ago
- Business Wire
Topbreed, SmartHeart, and Superdogs Among Winners at 2025-2026 World Branding Awards Animalis Edition in Vienna
LONDON--(BUSINESS WIRE)--The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from every corner of the globe. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. 'The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,' said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominated by more than 80,000 consumers in a global online survey, only the top 105 brands from 25 countries achieved the coveted title of winner. Earning a World Branding Award is a significant achievement, solidifying their status as industry leaders. Proving their excellence and impeccable branding, the Global tier winners include Frontline (Germany), Kit Cat (Singapore), KONG (UK), Sheba (USA), and Whiskas (USA). Winners from The Philippines include Topbreed, SmartHeart, and Superdogs. Other National tier winners include Bamboodles (UK), CIAO (Japan), Cooper and Gracie (UK), Delibest (Switzerland), Heads Up For Tails (India), Kaniva (Thailand), Kasty (Thailand), Nutriment Natural Treats (UK), Pampered Pets (Singapore), Petio (Japan), Powercat (Malaysia), Pramy (Thailand), and Vancat (Türkiye), to name a few. Regional tier winners include Alps Natural (Malaysia), EHEIM (Germany), and Hikari (Japan). These brands were voted as consumers' favourites in 4 or more countries across 3 or more areas in a specific geographic region. As the 2025-2026 World Branding Awards Animalis Edition concludes, the highly anticipated Global Edition of the World Branding Awards is set to return to the stage this November. For more information, visit The World Branding Awards is the premier award of the World Branding Forum, a registered non-profit organisation. The awards recognise the achievements of some of the world's best brands.


Business Wire
23 minutes ago
- Business Wire
Heads Up For Tails, Himalaya, and Taiyo Among Winners at 2025-2026 World Branding Awards Animalis Edition in Vienna
LONDON--(BUSINESS WIRE)--The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from all around the world. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. 'The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,' said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominated by more than 80,000 consumers in a global online survey, only the top 105 brands from 25 countries achieved the coveted title of winner. Earning a World Branding Award is a significant achievement, solidifying their status as industry leaders. Proving their excellence and impeccable branding, the Global tier winners include Frontline (Germany), Kit Cat (Singapore), KONG (UK), Sheba (USA), and Whiskas (USA). Winners from India include Heads Up For Tails, Drools, Himalaya, and Taiyo. Other National tier winners include Bamboodles (UK), CIAO (Japan), Cooper and Gracie (UK), Delibest (Switzerland), Kelly & Co's (Thailand), Nutriment Natural Treats (UK), Pampered Pets (Singapore), Petio (Japan), Powercat (Malaysia), Topbreed (The Philippines), and Vancat (Türkiye), to name a few. Regional tier winners include Alps Natural (Malaysia), EHEIM (Germany), and Hikari (Japan). These brands were voted as consumers' favourites in 4 or more countries across 3 or more areas in a specific geographic region. As the 2025-2026 World Branding Awards Animalis Edition concludes, the highly anticipated Global Edition of the World Branding Awards is set to return to the stage this November. For more information, visit The World Branding Awards is the premier award of the World Branding Forum, a registered non-profit organisation. The awards recognise the achievements of some of the world's best brands.